Alphamab Oncology (HKSE:09966) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09966 Alphamab Oncology HKSE:09966
55 GF Score
Price HK$8.35
GF Value HK$7.81
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:09966
55GF Score
Alphamab Oncology HKSE:09966
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alphamab Oncology (HKSE:09966) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of HK$8.35 is trading 6.9% above its estimated GF Value™ of HK$7.81. GuruFocus considers Alphamab Oncology to be Fairly Valued.

Key valuation signals for HKSE:09966:

  • FFO:
  • GF Value™: HK$7.81 vs. price of HK$8.35 (6.9% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the HKSE:09966 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alphamab Oncology Business Description

Other Exchanges 3NK:Germany
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score

Get the complete analysis for HKSE:09966

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$8.35
Price
HK$7.81
GF Value